SEOM‑GETNE‑TTCC Clinical guideline thyroid cancer (2023)

• Teresa Alonso Gordoa ^[1] ; Paula Jimenez Fonseca ^[2] ; Javier Martinez Trufero ^[3] ; Miguel Navarro ^[4] ; Ignacio Porras ^[5] ; Jordi Rubió Casadevall ^[9] ; Marta Arregui Valles ^[6] ; Neus Basté ^[7] ; Jorge Hernando ^[10] ; Lara Iglesias Docampo ^[8]
  1. [1] Hospital Ramón y Cajal

     Hospital Ramón y Cajal

     Madrid, España

     
  2. [2] Hospital Universitario Central de Asturias

     Hospital Universitario Central de Asturias

     Oviedo, España

     
  3. [3] Hospital Miguel Servet

     Hospital Miguel Servet

     Zaragoza, España

     
  4. [4] Hospital Universitario de Salamanca

     Hospital Universitario de Salamanca

     Salamanca, España

     
  5. [5] Instituto Maimónides de Investigación Biomédica de Córdoba

     Instituto Maimónides de Investigación Biomédica de Córdoba

     Cordoba, España

     
  6. [6] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  7. [7] Hospital Clinic Barcelona

     Hospital Clinic Barcelona

     Barcelona, España

     
  8. [8] Hospital Universitario 12 de Octubre

     Hospital Universitario 12 de Octubre

     Madrid, España

     
  9. [9] Medical Oncology Department, Catalan Institute of Oncology of Girona, Hospital Josep Trueta. ONCOGIRPRO Group, Girona Biomedical Research Institute (IDIBGI), Girona, Spain
  10. [10] Medical Oncology Department, Gastrointestinal and Endocrine Tumor Unit, Hospital Universitario Vall D’Hebron, VHIO, Barcelona, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 11, 2024, págs. 2902-2916
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Thyroid cancer (TC) represents 3% of global cancer incidence. Recent changes have optimized treatment decisions based on risk assessment, molecular profling, and imaging assessment, leading the development of targeted agents that have modifed the natural history of this disease. This increasing complexity on treatment options requires careful assessment at the diferent stages of the disease to provide the most suitable approach from diagnosis to long-term follow-up. This guideline aims to ofer a comprehensive and practical overview on the current status and last updates of TC management.